Long-term evaluation of SARS-CoV-2 antibody assays using mild symptomatik patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028039

Enrollment

Registered

2022-02-08

Start date

2022-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1G U09.9G

Interventions

Group 1: Mild symptomatic SARS-CoV-2 patients, that were not hospitalized, are asked to fulfill 2 questionaires regarding their COVID-19 and Post-COVID-19 symptoms. Retrospective inclusion of repeated

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: mild COVID-19 symptoms and a positive result of SARS-CoV-2 RT-PCR in a nasopharyngeal swab and repeated antibody determinations over a longer period of time

Exclusion criteria

Exclusion criteria: hospitalisation, missing SARS-CoV-2 RT-PCR report, SARS-CoV-2 reinfection

Design outcomes

Secondary

Measure	Time frame
not determined	—

Primary

Measure	Time frame
Long term evaluation of 1.) mild symptomatik patients up to the timepoint of the first vaccination 2.) vaccinated individuals up to 6 months after second vaccination	—

Countries

Germany

Contacts

Public ContactJessica Brehm

MVZ Medizinische Labore Dessau Kassel GmbH

jessica.brehm@laborpraxis-dessau.de0340 5405371

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026